Placing New MPN Therapies into Context Through Illustrated Case Discussions


Advances in the understanding of the pathogenesis of the myeloproliferative neoplasms (MPNs), polycythemia vera (PV) and primary myelofibrosis (MF), have led to improved treatment interventions. Approximately 95% of patients with PV and 50% of patients with MF have mutations in Janus kinase 2 (JAK2), which is essential for the normal development of granulocytes, erythrocytes, and platelets. Other less common shared mutations include CALR (calreticulin mutation) and MPL (myeloproliferative leukemia virus oncogene). Identification of mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies is paramount to improving outcomes for patients.

June 5, 2022 | Hilton Chicago, ILĀ 

Read More

Next Post

Prospect Medical Holdings Announces Partnership with Angeles-IPA

Prospect Medical Holdings (PMH) has announced a partnership with Angeles-IPA, A Medical Corporation (AIPA), to expand the integrated delivery system (IDS) to integrate PMH’s Coordinated Regional Care (CRC) system and AIPA’s physician network. This partnership will ensure quality healthcare is available to approximately 30,000 new beneficiaries of the Medi-Cal population […]